All Vaccinology articles
-
NewsHow one flu virus can hamper the immune response to another
Prior exposure to one strain of influenza virus may weaken children’s ability to mount an effective antibody response against their subsequent exposure to a different flu strain, according to a study.
-
NewsDengue vaccine remains 80.5% effective against severe cases after five years
The tetravalent dengue vaccine was 80.5% effective against severe dengue cases with warning signs over a five-year period. Overall, the vaccine was 65% effective in preventing symptomatic dengue (caused by any serotype) during the five years of monitoring.
-
NewsBuilding protection against infectious diseases with nanostructured vaccines
Researchers have leveraged a recently developed highly versatile DNA origami nanotechnology that is both vaccine and adjuvant, named DoriVac, as an alternative to current vaccine platforms.
-
NewsStudy finds natural fungal supplement improves COVID-19 vaccine response
Researchers have found that a natural fungal supplement taken at the time of COVID-19 vaccination reduced short-term vaccine side effects and helped antibodies last longer in people who had not previously been exposed to the virus.
-
NewsNanoparticle vaccine approach takes on a new target: Hepatitis C virus
Scientists have engineered a native-like, stabilized version of Hepatitis C virus’s E1E2 complex and used it to build a nanoparticle-based vaccine candidate. It uses a technology called self-assembling protein nanoparticles, which organizes copies of the proteins into virus-like clusters that the immune system can recognize.
-
NewsStudy reveals immune blueprint for next-generation malaria vaccine
New research has uncovered how the human immune system fights Plasmodium vivax, paving the way for the first effective vaccine against the most widespread form of malaria. It provides critical evidence of how protective immunity to P. vivax works, identifying specific targets on the parasite.
-
NewsHPV vaccination provides “sustained protection” against cervical cancer
Human papillomavirus (HPV) vaccination is associated with a significantly reduced risk of invasive cervical cancer, with no indication of waning protection up to 18 years after vaccination, finds a study.
-
NewsVaccine uptake: Why conspiracy theories can be so irresistible
New research has found that understanding how someone processes information can be a strong predictor of whether they are drawn to conspiracy beliefs that can influence vaccine uptake, trust in institutions and responses to emergencies.
-
NewsMeningococcal B vaccination does not reduce gonorrhoea, trial results show
Contrary to existing evidence from observational studies, the meningococcal B vaccine (4CMenB) has no effect on preventing the acquisition of gonorrhoea, according to the results of the world’s largest randomised control trial (RCT) into possible efficacy.
-
NewsHoly Grail: One vaccine may provide broad protection against many respiratory infections and allergens
In a new study in mice, researchers have developed a universal vaccine formula that protects against a wide range of respiratory viruses, bacteria and even allergens.
-
NewsMissed opportunity: Study shows low vaccination rates among expectant mothers in Norway against COVID-19 and influenza
A study of over 50,000 pregnant women in Norway during the 2023/24 influenza season found that only 29.9% were vaccinated against influenza and 12.1% against COVID-19 during pregnancy, remaining far below recommended targets.
-
NewsNew review points to faster, safer vaccine development
A new review examines viral mimic systems that reproduce key features of dangerous pathogens such as SARS-CoV-2, the virus that causes Covid-19, without the ability to replicate or cause disease. These systems allow researchers to study infection safely, quickly, and in a wider range of laboratories.
-
NewsNovel vaccine protects against C. diff disease and recurrence
A novel vaccination approach cleared the harmful gut bacterium Clostridioides difficile in an animal model of infection. An experimental vaccine administered to the mucosal lining of the colon protected against illness, death, tissue damage and infection recurrence.
-
NewsBooster jabs reduce the risks of COVID-19 deaths, study finds
Booster vaccines reduced the risk of COVID‑19–related hospitalisation and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England.
-
NewsCOVID-19 vaccination during pregnancy may help prevent preeclampsia
A new multinational study has found that COVID-19 vaccination during pregnancy, particularly when combined with a booster dose, significantly reduces the risk of preeclampsia, a serious and potentially life-threatening pregnancy complication.
-
NewsNo association between mRNA COVID-19 vaccination during pregnancy and autism in children, new research shows
The mRNA COVID-19 vaccine is not associated with autism or other neurodevelopmental problems in children whose mothers received the vaccine immediately before or during pregnancy, according to new research.
-
NewsOne strategy to block both drug-resistant bacteria and influenza: new broad-spectrum infection prevention approach validated
A new paper moves beyond traditional infection control strategies reliant on antibiotics and vaccines by introducing a new approach that primes the immune system before infection occurs.
-
NewsHIV antibody opens up new approaches for vaccine development and combination therapies
An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. The study opens up new perspectives for the development of vaccines and therapeutics against HIV-1.
-
NewsHPV cancer vaccine slows tumor growth, extends survival in preclinical model
Scientists discovered that systematically changing the orientation and placement of a single cancer-targeting peptide can lead to formulations that supercharge the immune system’s ability to attack HPV-driven tumors.
-
NewsResearchers solve mystery behind rare clotting after adenoviral vaccines or natural adenovirus infection
Scientists have uncovered why a small number of people developed dangerous blood clots after either receiving certain COVID‑19 vaccines or experiencing a natural adenovirus infection - the answer lies in an unexpected case of misdirected targeting by the immune system.